Feb 2021 $65 M No. 8 $50 to $250 million 26
Hemaquest Pharmaceuticals: Raise no. 8, Feb 2021 × Investors in this round 26 investors had bought by the notice of Mar 10, 2021: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $65 M of $65 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Chevallard · Executive Officer Ivor Royston · Executive Officer, Director Gur Roshwalb · Director Michael Huang · Director Richard Ghalie · Director Roger Pomerantz · Director Samuel Murphy · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Daniel Chevallard, Chief Financial Officer and Chief Operating Officer. Source: SEC Form D, newest notice filed Mar 10, 2021. Read the notice at the SEC .
equity SEC Nov 2020 $40 M No. 7 $10 to $50 million 14
Hemaquest Pharmaceuticals: Raise no. 7, Nov 2020 × Investors in this round 14 investors had bought by the notice of Dec 10, 2020: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $40 M of $40 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Chevallard · Executive Officer Ivor Royston · Executive Officer, Director Gur Roshwalb · Director Michael Huang · Director Richard Ghalie · Director Roger Pomerantz · Director Samuel Murphy · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Daniel Chevallard, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 10, 2020. Read the notice at the SEC .
equity SEC Oct 2019 $17 M No. 6 $10 to $50 million 21
Hemaquest Pharmaceuticals: Raise no. 6, Oct 2019 × Investors in this round 21 investors had bought by the notice of Nov 5, 2019: 21 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $17 M of $25 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Daniel Chevallard · Executive Officer David Slack · Executive Officer Ivor Royston · Executive Officer, Director Barry Simon · Director James Woody · Director Michael Huang · Director Richard Ghalie · Director Samuel Murphy · Director Standish Fleming · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Daniel Chevallard, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 5, 2019. Read the notice at the SEC .
equity SEC Jan 2019 $6 M No. 5 $2 to $10 million 25
Hemaquest Pharmaceuticals: Raise no. 5, Jan 2019 × Investors in this round 25 investors had bought by the notice of Feb 12, 2019: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Slack · Executive Officer Ivor Royston · Executive Officer, Director Barry Simon · Director James Woody · Director Patrick Soon-Shiong · Director Richard Ghalie · Director Standish Fleming · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total Amount Sold was cancellation of indebtedness”Signed by Ivor Royston, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 12, 2019. Read the notice at the SEC .
equity SEC Nov 2018 $11 M No. 4 $10 to $50 million 6
Hemaquest Pharmaceuticals: Raise no. 4, Nov 2018 × Investors in this round 6 investors had bought by the notice of Feb 12, 2019: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $11 M of $11 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Slack · Executive Officer Ivor Royston · Executive Officer, Director Barry Simon · Director James Woody · Director Patrick Soon-Shiong · Director Richard Ghalie · Director Standish Fleming · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total Amount Sold includes $10,000,000.08 of new cash and $695,494.65 of cancellation of indebtedness”Signed by Ivor Royston, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 12, 2019. Read the notice at the SEC .
equity SEC Mar 2017 $10 M No. 3 $2 to $10 million 9
Hemaquest Pharmaceuticals: Raise no. 3, Mar 2017 × Investors in this round 9 investors had bought by the notice of Apr 5, 2017: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $27 M offered; $17 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Slack · Executive Officer Ivor Royston · Executive Officer, Director James Woody · Director Patrick Soon-Shiong · Director Richard Ghalie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “$8,799,999.02 in new money; $1,075,624.54 in conversion of promissory notes.”Signed by David Slack, Chief Business Officer. Source: SEC Form D, newest notice filed Apr 5, 2017. Read the notice at the SEC .
equity SEC Mar 2012 $7 M No. 2 $2 to $10 million 10
Hemaquest Pharmaceuticals: Raise no. 2, Mar 2012 × Investors in this round 10 investors had bought by the notice of Apr 4, 2012: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $16 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John P. Longenecker · Executive Officer, Director Richard P. Ghalie · Executive Officer Tamara P. Seymour · Executive Officer Armen P. Shanafelt · Director Fred P. Dotzler · Director George P. Stamatoyannopoulos · Director Ivor P. Royston · Director James P. Woody · Director Naheed P. Misfeldt · Director Paul P. Goddard · Director Wayne P. Roe · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tamara A. Seymour, Cfo. Source: SEC Form D, newest notice filed Apr 4, 2012. Read the notice at the SEC .
equity SEC Jan 2010 $16 M No. 1 $10 to $50 million 12
Hemaquest Pharmaceuticals: Raise no. 1, Jan 2010 × Investors in this round 12 investors had bought by the notice of Aug 2, 2010: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $16 M of $16 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark Handfelt · Executive Officer Ronald Berenson · Executive Officer, Director, Promoter Susan Perrine · Executive Officer Armen Shanafelt · Director Frederick Dotzler · Director George Stamatoyannopoulos · Director Ivor Royston · Director James N. Woody · Director Naheed Misfeldt · Director Paul Goddard · Director Wayne Roe · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Nancy P.A. Williams, Attorney-in-Fact. Source: SEC Form D and 1 amendment, newest notice filed Aug 2, 2010. Read the notice at the SEC .
equity SEC